没有股票账户的投资者可关注国泰中证医疗ETF联接A（012634），国泰中证医疗ETF联接C （012635）。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相 匹配的产品。基金有风险，投资需谨慎。 每日经济新闻 中信建投指出，医疗器械行业正迎来业绩与估值的双修复，把握轮动上涨机会。受集采政策优化、企业 战略转型及国际业务拓展推动，多家公司业绩拐点显现，预计25年下半年及26年将实现高增长。创新器 械赛道关注度提升，脑机接口、AI医疗、手术机器人等方向具备较大想象空间，相关临床进展及政策 催化有望持续。国际化成为重要成长逻辑，中国企业在改进式创新（me-too/me-better）和突破式创新 （如赛诺医疗颅内支架获FDA认定）方面逐步获得全球认可，海外业务高增长带动估值重塑。医疗设备 领域，联影、迈瑞等企业受益招标改善及库存出清，Q3业绩有望加速；高值耗材中骨科、电生理等赛 道集采影 ...

Group 1 - The pharmaceutical and biotechnology sector has increased by 25.02% this year, ranking 4th among 31 industries in the Shenwan index, with a current PE valuation of 31.31 times, at the historical median level [1] - Sub-sectors such as medical services, chemical pharmaceuticals, and medical devices have shown significant gains of 6.60%, 3.80%, and 2.22% respectively in the past week [1] - The National Healthcare Security Administration has issued a temporary measure for disease-based payment management, promoting payment reform and standardizing total budget management and disease payment standard calculations [1] Group 2 - The preliminary list of innovative drugs for medical insurance and commercial insurance for 2025 has been released, with several cancer drugs and chronic disease new drugs expected to see rapid growth after being included in the dual directory [1] - The medical device sector continues to receive policy support for innovation, with a recommendation to focus on niche areas such as brain-computer interfaces [1] - Under the release of industry policy dividends, there are investment opportunities in innovative drugs, CXO, and medical equipment sectors [1] Group 3 - The medical ETF (159828) tracks the CSI Medical Index (399989), which can have a daily fluctuation of up to 20%, reflecting the overall performance of listed companies involved in medical devices, medical services, and medical information technology [1] - The index primarily consists of companies in the pharmaceutical and biotechnology industry, while also including a small number of companies in the computer and beauty care sectors, focusing mainly on small and mid-cap enterprises [1]

Group 1 - The pharmaceutical and biotechnology industry has shown strong performance, with a 25.02% increase since the beginning of 2025, outperforming the CSI 300 index by 18.22 percentage points, ranking 4th in industry performance [1] - The preliminary review of the dual catalog for innovative drugs under basic medical insurance and commercial insurance has been published, with 534 drugs passing the basic medical insurance catalog review and 121 drugs passing the commercial insurance innovative drug catalog review. Antitumor drugs account for 29.2%, anti-infection drugs for 10.5%, and neurological drugs for 10.3% [1] - The sentiment in the innovative drug sector is high, exemplified by the 206.5% increase in the stock price of Silver诺药业 on its first day of trading in Hong Kong, with its core product being the first domestically approved long-acting GLP-1 receptor agonist in China [1] Group 2 - The medical device sub-sector has shown the best performance, with medical research outsourcing increasing by 59.6% since the beginning of the year, while chemical preparations and raw materials have risen by 44% and 42.6% respectively [1] - The overall supply and demand situation in the industry is favorable, driven by policy support and technological innovation, promoting continuous development [1] - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies involved in medical devices, medical services, and medical information technology to reflect the overall performance of medical-related listed companies [1]

Group 1 - The core viewpoint of the article emphasizes the policy direction of "supporting true innovation, supporting genuine innovation, and supporting differentiated innovation" in the context of medical insurance for innovative drugs and devices, rejecting pseudo-innovation and inward competition [1] - The meeting covers the entire policy system from research and development, value assessment, medical insurance access to capital support, accelerating the implementation of policies that will further stimulate industry innovation vitality and accelerate industrial upgrading [1] - Companies with independent innovation capabilities are expected to benefit in the long term as the industry evolves towards multi-dimensional development, transitioning from scale expansion to a higher level of development [1] Group 2 - The medical device sector showed strong performance with a July fluctuation of 14.27%, ranking second among six sub-sectors in the pharmaceutical and biological industry [1] - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects representative listed companies in the fields of medical services, medical devices, pharmaceuticals, and biotechnology from the Shanghai and Shenzhen markets [1] - The CSI Medical Index covers multiple sub-industries, including medical equipment, in vitro diagnostics, and high-value consumables, demonstrating strong industry representation [1]

Core Viewpoint - The launch of the Smart Medical Insurance Competition is expected to enhance the efficiency of innovative drug development in the pharmaceutical and biotechnology industry, with open medical insurance data aiding companies in accurately identifying clinical needs, thereby shortening development cycles and reducing costs [1]. Group 1: Industry Insights - The competition promotes cross-industry resource integration, potentially leading to new research and development models through collaboration between technology companies and pharmaceutical firms, accelerating the transition of innovative drugs from laboratory to clinical application [1]. - The innovative drug sector is projected to have high growth potential in the long term, with deeper applications of medical insurance data expected to improve both the quantity and quality of innovative drugs, which can achieve significant market share and pricing power post-approval due to clinical advantages [1]. - The reactivation of the dual financing channels of the Sci-Tech Innovation Board and Hong Kong's 18A is expected to invigorate the full-cycle financing of pharmaceutical companies, while new regulations on traditional Chinese medicine pieces are likely to accelerate industry consolidation, benefiting leading companies and distribution channels [1]. Group 2: ETF Information - The Medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the medical device, medical services, and medical information sectors from the Chinese A-share market to reflect the overall performance of related securities [1]. - The CSI Medical Index focuses on high-growth medical sectors, selecting about 50 stocks with good liquidity and large market capitalization, and undergoes adjustments every six months, showing significant sensitivity to policy changes [1]. - Investors without stock accounts can consider the Guotai CSI Medical ETF Connect A (012634) and Guotai CSI Medical ETF Connect C (012635) [1].

Core Insights - The pharmaceutical and biotechnology sector has recently experienced significant growth, driven by ongoing trends in innovative drugs and CXO markets, with continuous catalysts emerging [1] - Recent policies, including the "Several Measures to Support the High-Quality Development of Innovative Drugs" and notifications regarding the 11th batch of centralized procurement, are crucial for the pharmaceutical and medical device sectors [1] - The innovative drug policy supports development across the entire chain from research and development to market access and payment, while the 11th batch of centralized procurement emphasizes principles such as "stabilizing clinical practices, ensuring quality, preventing collusion, and countering internal competition" [1] - The sector is showing signs of recovery, with a potential inflection point in performance on the horizon, and investment opportunities arising from the optimization of centralized procurement rules in the medical device sector [1] Industry Overview - The Medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies involved in medical devices, medical services, and biopharmaceuticals from the Shanghai and Shenzhen markets to reflect the overall performance of the medical industry [1] - The CSI Medical Index focuses on the healthcare sector and covers representative enterprises within the industry, effectively reflecting market characteristics and development trends [1] - Investors without stock accounts can consider the Guotai CSI Medical ETF Link A (012634) and Guotai CSI Medical ETF Link C (012635) [1]

Group 1 - The core viewpoint of the articles emphasizes the positive impact of the National Medical Insurance Administration's discussions on the medical device industry, promoting high-quality development through principles like "anti-involution," overseas expansion, and differentiated innovation [1] - The collection prices for medical devices are expected to stabilize and improve company profitability, while policies will stimulate innovation and research and development (R&D) in the medical device sector, leading to new product launches and growth opportunities [1] - The Chinese pharmaceutical market is undergoing a phase of increasing concentration, with mergers and acquisitions expected to accelerate, indicating a shift towards a more consolidated market structure [1] Group 2 - The medical ETF (159828) tracks the CSI Medical Index (399989), which includes listed companies in medical devices, medical services, pharmaceutical commerce, and biopharmaceuticals, reflecting the overall performance of the medical industry [1] - The index is growth-oriented, suitable for investors interested in the long-term growth potential of the healthcare sector [1]

Group 1 - The pharmaceutical and biotechnology industry is experiencing high growth in innovative drugs, with recent government statements supporting innovation and addressing internal competition [1] - The National Healthcare Security Administration has indicated that the 11th batch of centralized procurement will optimize rules, moving away from solely considering the lowest bid [1] - The A-share pharmaceutical sector outperformed in the fourth week of July 2025, with the SW pharmaceutical and biotechnology index rising by 1.9%, and sub-sectors like medical services (+6.7%) and medical devices (+4.4%) showing strong performance [1] Group 2 - The medical device industry is expected to benefit from policy optimization, leading to sustained growth [1] - The overall premium rate of the pharmaceutical sector relative to all A-shares is at a normal level of 88.0%, with innovative drugs and their supply chain maintaining high growth [1] - The CSI Medical Index, which tracks companies in the medical device, medical service, and biopharmaceutical sectors, reflects the overall performance of representative enterprises in the healthcare industry [1] Group 3 - Investors without stock accounts can consider the Guotai CSI Medical ETF Link A (012634) and Guotai CSI Medical ETF Link C (012635) [1]

Group 1 - The medical ETF (159828) rose over 2.1% on July 29, indicating a positive trend in the healthcare sector [1] - The pharmaceutical and biopharma/biotech industries are expected to see a revaluation of value due to high demand for innovative drugs and the realization of innovation pipelines [1] - The medical device industry is likely to benefit from policy optimization, with recent statements from relevant authorities supporting innovation and indicating changes in procurement rules [1] Group 2 - The medical ETF (159828) tracks the CSI Medical Index (399989), which includes listed companies involved in medical devices, medical services, and pharmaceutical commerce [1] - The index reflects the overall performance of companies in the healthcare sector and covers multiple sub-sectors, showcasing the diversity within the industry [1] - The medical sector's performance is expected to continue benefiting from policy support and growing industry demand, particularly in innovative drugs and medical devices [1]

Group 1 - The pharmaceutical and biotechnology sector has shown strong performance recently, particularly in the medical services and medical devices sub-sectors [1] - The National Healthcare Security Administration (NHSA) has held two meetings to support innovative drugs and medical devices, indicating a commitment to integrating high-level technological innovations into clinical practice and promoting the globalization of Chinese medical products [1] - Since June 2025, the regulatory framework for high-end medical devices has been increasingly supportive of innovation, with a focus on "genuine support for innovation, supporting true innovation, and supporting differentiated innovation" [1] Group 2 - The NHSA emphasized that the selection process for centralized procurement will no longer simply reference the lowest price, suggesting that orderly competition will dominate the industry, potentially enhancing profitability and valuation levels in the medical device sector [1] - The current price-to-earnings (PE) ratio for the pharmaceutical and biotechnology sector is 30.67, which is at the historical median level, while the medical device sub-sector has a PE ratio of 32.91, indicating a significant upward trend in the industry under the new policy environment [1]